The US Food and Drug Administration (FDA) has approved AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for ...
FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...
FluMist has been sold at pharmacies for years, but now it will be available to use at home as early as next year.
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on ...
The FDA has approved at-home self- or caregiver-administration of FluMist (influenza vaccine live, intranasal).
The FDA has approved FluMist (AstraZeneca) for self-administration by adults up to age 49 years or for caregiver administration for children aged 2 to 17 years, making it the first self-administered ...
Next year’s flu season will have an additional option for people looking to protect themselves: a flu vaccine that can be ...
Next year’s flu season will have an additional option for people looking to protect themselves: a flu vaccine that can be ...
AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...
The FDA has approved the at-home use of AstraZeneca's FluMist nasal spray vaccine. A prescription will still be required. The vaccines will be available from an on-line pharmacy next fall.
FluMist, a needle-free nasal spray influenza vaccine, has been approved by the FDA for self-administration in the US, making ...
FluMist approved for self-administration in the US Only influenza vaccine approved for self- or caregiver-administration at home, expanding options for influenza protection FluMist ...